Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"We’ll have something to say about that in the 10q we file probably tomorrow" refers to the approval in the 10Q flipper, it does not refer to "the fall"
This ASM has been called SOLY because management is in a panic and needs new arguments in the true-up lawsuit. If the true up law suit did not exist we would not have an ASM this month, in that case, they would have waited until after UK approval.
There is not going to be approval in the next three weeks. If there would be approval in the next three weeks management would have made sure to have the proxy vote after that for that argument would have sat much better in the True-up lawsuit. Thats what I have been saying here a few times now. The Delaware court's reasoning for why management should not have this reward in options/warrant will not change after this third or 4th vote. The court may very well have another allowed management's option warrant reward if the vote had occurred after UK approval.
I voted no.
sounds very reasonable yes.
Look at Outlook therapeutics stock -40% sinds EMA approval.
The ONLY way to get NWBO stock uplisted and substantial up is with large non dilutive financial injections.
its insane you suggesting NWBO management supporting shorts, thats insane. and no that does not happen al the time.
any child could have done this financing better by simply doing an ATM financing over the last 2 months
I hope you are right of course but if you read the ASM's agenda then the ASM is ALL about getting new arguments for management for the true-up lawsuit. Thats it nothing else, for this ASM its all about THEM.
exactly
good grief
3 posters already, unaware of what the difference is between 450,000 = 450k and 4.5 million = 4,500k
thank you flipper
you are as relevant as a cockroach with your 4500 shares diarrhea for brains KIPK
I cant post indefinitely moron, I have a 15-post per day max.
Are you still short Mionaer or have you turned your short NWBO position already?
you got all this text vomit:
from ai ai ai? 🤣
Unrelated question but, do they have good mental health professionals in Denmark?
Desperate whining and begging. Im voting NO with my 450k shares
Non of the arguments outlined below will change the mind of the Delaware court
yes but unfortunately also reality
Ir really is a bit TOO convenient NVCR presenting a small improvement of mOS compared to DCVAXL's mOS for nGBM right when DCVAXL is in the middle of its approval process. Especially when they have proven to twist, lie, and bend their trial stats before. I bet the latest GBM data NVCR presented will never be published in any meaningful medical article.
DCVAXL will still be approved by the MHRA and other RA's. Im however no longer convinced DCVAXL will be promoted to be the SOC for nGBM based on the data submitted to the MHRA
And YES fipper and others will ignore my post
Interesting
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938032/ Published online 2024 Mar 13
Cancer vaccines such as peptide vaccines and DC vaccines have shown great promise in glioma immunotherapy. In one ongoing single-arm single-center open-label phase I clinical trial that included 13 ndGBM patients, a poly-ICLC tumor vaccine was administered in the TMZ and TTField phases after chemoradiotherapy to explore the safety and potential clinical benefits of the tumor vaccine combined with TTFields. The primary outcome measure of this trial is dose-limiting toxicity, and the secondary outcome measures are the toxicity grade, PFS, OS, and overall response rate (ORR). DC vaccine therapy starts with the isolation of DCs from the patient's blood followed by exposure of the DCs to a tumor sample from the patient and activation of the DCs. The activated DCs are then transfused back into the patient to activate the immune system and kill cancer cells. In a multicenter prospective phase III trial, the DCVax-L vaccine was added to the chemoradiotherapy and adjuvant TMZ treatment phase of standard care (surgery/RT/TMZ). The results showed significantly better OS in ndGBM patients treated with DCVax-L than in those treated with standard therapy. The risk of death at any time point was reduced by 20%, and this survival benefit increased over time. As mentioned above, TTFields can recruit and activate DCs; therefore, does combining DCVax-L with TTFields produce a more powerful antitumor effect? In this trial, eight patients were treated with TTFields after tumor recurrence. Four patients (50.0%) were treated with DCVax-L and survived for 22.6–72.7?months after randomization. As controls, four patients (50.0%) stopped DCVax-L therapy and survived for between 8.9 and 29.2?months after randomization. 70 These preliminary results suggest that TTFields combined with DCVax-L is a beneficial treatment regimen, but larger trials are needed to verify its safety and efficacy.
you really are insane and sick in your brian
I quoted press releases from the real world not adding any opinion and I'm getting a middle finger.
If you cant handle reality then you should lock the door of your mamma's basement where you live.
ai ai ai ai ai
Novocure: Median overall survival for patients treated with TTFields therapy was 19.6 months
NWBO: reported that the median overall survival for a newly diagnosed GBM patient treated with the vaccine was 19.3 months
https://www.novocure.com/tiger-study-reports-new-ttfields-therapy-survival-results-for-newly-diagnosed-glioblastoma-patients-in-germany/
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
May 23, 2024
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM
Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine clinical care completed to date.
Median overall survival for patients treated with TTFields therapy was 19.6 months (95% CI, 17.9-22.4). Median progression-free survival was 10.2 months (95% CI, 9.4-11.4). TTFields therapy use was not associated with an increase in systemic toxicity and was well tolerated. The outcomes observed in the TIGER study are consistent with the survival and safety results from Novocure’s phase 3 EF-14 clinical trial.
Patients were followed for a median duration of 56.2 months. One-, two-, three-, and four- year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively.
“As TTFields therapy use becomes more prevalent around the globe, it is exciting to see large, prospective studies like TIGER corroborate the survival benefits provided by using TTFields therapy to treat newly diagnosed GBM,” said Oliver Bähr, MD, Department of Neurology, General Hospital Aschaffenburg-Alzenau. “The outcomes observed, particularly long-term survival rates, are promising and make a compelling case that TTFields therapy should be presented to all eligible GBM patients.”
“TIGER is the largest prospective, non-interventional study analyzing TTFields therapy use in newly diagnosed GBM completed to date,” said Nicolas Leupin, MD, Novocure’s Chief Medical Officer. “The observations from TIGER contribute to the multitude of data validating the use of TTFields therapy, and we are eager to continue exploring the benefits of our therapy in both the clinical and real-world settings.”
The TIGER data (abstract #2036) will be presented at 9:00 a.m. CDT on Saturday, June 1, 2024 in Hall A during the Central Nervous System Tumors session at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.
thats correct Im saying that
unbelievable that we agree.
yes that is insane. They are very desperate. Also as far as I can see there is absolutely NOTHING that is being brought forward by management as a justification that would prompt the Delaware court to think differently from the Tue Up case. NOTHING. So why they are going for a third vote is beyond me.
What I do not understand is that they wait until after UK approval to ask for this vote so they can offer that is a justification for their increase in options and warrants reward.